Vanguard Group Inc Lineage Cell Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $6.44 Trillion
  • Q3 2025

A detailed history of Vanguard Group Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 9,006,930 shares of LCTX stock, worth $17.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,006,930
Previous 8,482,873 6.18%
Holding current value
$17.1 Million
Previous $7.72 Million 101.85%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 07, 2025
BUY
$0.87 - $1.79 $455,929 - $938,062
524,057 Added 6.18%
9,006,930 $15.6 Million
Q2 2025

Aug 11, 2025
SELL
$0.39 - $1.13 $170,106 - $492,872
-436,170 Reduced 4.89%
8,482,873 $7.72 Million
Q1 2025

May 09, 2025
BUY
$0.45 - $0.72 $128,751 - $206,002
286,115 Added 3.31%
8,919,043 $4.01 Million
Q4 2024

Feb 11, 2025
BUY
$0.5 - $0.95 $15,966 - $30,336
31,933 Added 0.37%
8,632,928 $4.32 Million
Q3 2024

Nov 13, 2024
BUY
$0.8 - $1.12 $101,622 - $142,271
127,028 Added 1.5%
8,600,995 $7.83 Million
Q2 2024

Aug 13, 2024
BUY
$0.89 - $1.47 $89,174 - $147,288
100,196 Added 1.2%
8,473,967 $8.47 Million
Q1 2024

May 10, 2024
SELL
$0.86 - $1.48 $9,387 - $16,155
-10,916 Reduced 0.13%
8,373,771 $12.4 Million
Q4 2023

Feb 14, 2024
BUY
$0.91 - $1.35 $65,843 - $97,679
72,355 Added 0.87%
8,384,687 $9.14 Million
Q3 2023

Nov 14, 2023
BUY
$1.16 - $1.53 $1.33 Million - $1.76 Million
1,150,633 Added 16.07%
8,312,332 $9.81 Million
Q2 2023

Aug 14, 2023
BUY
$1.26 - $1.53 $827,518 - $1 Million
656,761 Added 10.1%
7,161,699 $10.1 Million
Q1 2023

May 15, 2023
BUY
$1.2 - $1.53 $477,460 - $608,762
397,884 Added 6.52%
6,504,938 $9.76 Million
Q4 2022

Feb 10, 2023
BUY
$1.02 - $1.5 $158,672 - $233,341
155,561 Added 2.61%
6,107,054 $7.15 Million
Q2 2022

Aug 12, 2022
SELL
$1.12 - $1.61 $6,090 - $8,755
-5,438 Reduced 0.09%
5,951,493 $9.4 Million
Q1 2022

May 13, 2022
SELL
$1.21 - $2.48 $5,716 - $11,715
-4,724 Reduced 0.08%
5,956,931 $9.17 Million
Q4 2021

Feb 14, 2022
BUY
$1.84 - $2.68 $9,238 - $13,456
5,021 Added 0.08%
5,961,655 $14.6 Million
Q3 2021

Nov 12, 2021
SELL
$2.26 - $2.86 $999,329 - $1.26 Million
-442,181 Reduced 6.91%
5,956,634 $15 Million
Q2 2021

Aug 13, 2021
BUY
$2.17 - $3.0 $13.9 Million - $19.2 Million
6,398,815 New
6,398,815 $18.2 Million

Others Institutions Holding LCTX

# of Institutions
128
Shares Held
96M
Call Options Held
251K
Put Options Held
50K
View Full List

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $323M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email